Navigation Links
Equashield Releases Market's Safest Closed System Drug Transfer Device for Medical Professionals
Date:12/9/2013

PORT WASHINGTON, New York, December 9, 2013 /PRNewswire/ --

Equashield (http://www.equashield.com/), the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, today announced the launch of Equashield II, the safest closed drug transfer system for medical professionals. Equashield II, the only solution that prevents contamination of syringe plungers by hazardous drugs, represents a breakthrough in medical occupational safety, specifically for pharmacists and nurses.

"We are proud to unveil our second generation, market-leading solution, Equashield II," said Marino Kriheli, Product Manager for Equashield. "Other products on the market offer medical professionals dealing with chemotherapy and other hazardous drugs partial or no protection. By covering more routes of exposure than ever, this product is a truly closed system, and as such, provides medical professionals with unprecedented safety. With its preassembled unique syringe it is also easier and faster to use than any other system, increasing overall hospital productivity."

  • Equashield II is a Closed System Transfer Device with closed pressure equalization and "dry" connectors integrated into a unique syringe. The encapsulated syringe barrel prevents plunger contamination and accidental disconnections. The pre-assembled syringe connects with a single motion to corresponding adaptors for vials, IV bags and tubing.
  • Equashield II is proven to prevent microbial ingress in media-filled vials after repeated inoculation with bacteria and up to 10 vial accesses and transfers, over 7 days of testing, under the most extreme conditions. This provides protection to patients and has demonstrated the potential of extending Beyond Use Dating for single-use or non-preserved drugs, given current USP Chapter 797.
  • Equashield II is the only preassembled syringe on the market that requires no further setup, enabling quicker deployment times than other closed systems.

Equashield's first generation device was initially deployed in 2010 at Cleveland Clinic, and is currently used in more than 200 hospitals and clinics in the U.S. committed to ensuring the safety of medical professionals and patients.

Equashield II was launched at ASHP's Midyear Clinical Meeting, the largest event for pharmacists and pharmacy professionals in the world. Equashield will be exhibiting at the ASHP Meeting through December 11th and can be visited at booth #707.

About Equashield

Equashield is a leading developer of closed system drug transfer devices that protect healthcare professionals from hazardous drug and vapor exposure. EQUASHIELD® is clinically proven to eliminate surface contamination with antineoplastic agents and prevent microbial ingress, having demonstrated the ability to extend beyond-use dating for single-use or non-preserved drugs. The system consists of a unique syringe with encapsulated barrel and plunger, built-in closed pressure equalization, and an integrated single motion connector that remains free of drug residuals after multiple connections. EQUASHIELD® is the only preassembled syringe on the market that requires no further setup, thereby contributing to ease of use and overall hospital productivity. For more information, visit the company's website at http://www.equashield.com/.

Media Contact:
Finn Partners Israel for Equashield
Rachel Glaser
+972-54-250-9439
rachel@finnpartners.co.il


'/>"/>
SOURCE Equashield
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
2. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
3. ShelfX Releases A Fridge That Knows What You Took
4. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
5. Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System
6. Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events
7. Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial
8. MD Bioproducts releases HLA-B27 subtype specific antibody.
9. ChemDAQ Releases First Sensor For Detection Of Peracetic Acid In Air
10. Polar Releases H7, a Preeminent Wireless Heart Rate Sensor with Bluetooth Smart
11. NanoMarkets Releases New Report on Thin-Film and Printed Batteries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):